Results 21 to 30 of about 24,570,112 (250)
Frontiers in Medicine, 2023 Inflammatory Bowel Disease (IBD) affects approximately 0.3% of the global population, with incidence rates rising dramatically worldwide. Emerging evidence points to an interplay between exposome factors such as diet and gut microbiota, host genetics ...
Allan Stensballe +17 more
doaj +1 more source
Effects of P-Glycoprotein and Its Inhibitors on Apoptosis in K562 Cells
Molecules, 2014 P-glycoprotein (P-gp) is a major factor in multidrug resistance (MDR) which is a serious obstacle in chemotherapy. P-gp has also been implicated in causing apoptosis of tumor cells, which was shown to be another important mechanism of MDR recently.
Yaqiong Zu +4 more
doaj +1 more source
Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein. [PDF]
PLoS ONE, 2011 Human P-glycoprotein (P-gp) is an ATP-binding cassette multidrug transporter that confers resistance to a wide range of chemotherapeutic agents in cancer cells by active efflux of the drugs from cells.
Zsolt Bikadi +10 more
doaj +1 more source
An updated patent review on P-glycoprotein inhibitors (2011-2018) [PDF]
, 2019 Introduction: P-glycoprotein is a complex ATP-ase transporter involved in physiological and pathological functions. In particular, it is involved in the onset of multidrug resistance in cancer, in ocular disease, Chronic Rhinosinusitis, CNS diseases ...
Contino M +5 more
core +3 more sources
Multidrug resistance factor - glycoprotein P in rheumatoid arthritis
Научно-практическая ревматология, 2003 Objective. To assess expression of P-glycoprotein (Pgp) on peripheral blood (PB) lymphocytes and its changes during therapy in pts with rheumatoid arthritis (RA). Methods. 51 RA pts and 11 healthy donors (control group) were examined.
I P Kolosova
doaj +1 more source
Química Nova, 2010 Multidrug resistance, MDR is a major obstacle for cancer chemotherapy. MDR can be reversed by drugs that vary in their chemical structure and main biological activity.
Paula C. Huber +2 more
doaj +1 more source
P-glycoprotein Inhibition for Optimal Drug Delivery
Drug Target Insights, 2013 P-glycoprotein (P-gp), an efflux membrane transporter, is widely distributed throughout the body and is responsible for limiting cellular uptake and the distribution of xenobiotics and toxic substances. Hundreds of structurally diverse therapeutic agents
Md. Lutful Amin
doaj +2 more sources
Pharmaceutics, 2023 Triple-negative breast cancer (TNBC) is a highly aggressive disease with rapid progression and poor prognosis due to multidrug resistance (MDR).
Wenwen Xu +5 more
doaj +1 more source
SUBSTRATE-BASED NOVEL DIMERIC PRODRUG INHIBITORS OF HUMAN P-GLYCOPROTEIN
, 2022 The human multidrug resistance transporter P-glycoprotein (P-gp) is highly expressed at blood- tissue barriers, including the blood-brain barrier (BBB), and poses a serious challenge for the delivery of therapeutics to the brain. Additionally, expression
Elias George Beretta (14228159)
core +1 more source
MoleculesP-Glycoprotein (P-gp, also known as MDR1 or ABCB1) is an ATP-binding cassette (ABC) transporter that actively effluxes a wide range of structurally and functionally diverse molecules, playing a crucial role in drug absorption, distribution, and excretion.
Francesco Mastropasqua +3 more
doaj +1 more source